MedTrace Logo

Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics

NCT01411930 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2012-12-20

No results posted yet for this study

Summary

Antipsychotic medicines used to treat mental illnesses have been associated with effects on blood sugar control. Laboratory studies have shown that certain medications in particular may alter how insulin works. One purpose of this study is determine if antipsychotic medications have immediate effects on insulin action in individuals who do not have a mental disorder, but who have risk factors for diabetes. A second purpose is to demonstrate the feasibility of using volunteers without psychiatric disorders, and who do not take psychiatric medications, as a means for studying antipsychotic metabolic effects.

Conditions

Interventions

DRUG

Intramuscular olanzapine, aripiprazole

1. 1st clamp: single intramuscular 10.0 mg dose of olanzapine 2. 2nd clamp: single intramuscular 9.75 mg dose of aripiprazole

DRUG

Intramuscular aripiprazole, olanzapine

1. 1st clamp: single intramuscular 9.75 mg dose of aripiprazole 2. 2nd clamp: single intramuscular 10.0 mg dose of olanzapine

Sponsors & Collaborators

Principal Investigators

  • Jonathan M Meyer, MD · VA San Diego and VMRF

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-03-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01411930 on ClinicalTrials.gov